Fin Medium

Industry Overview Industry at large is experiencing operating deleverage in this financial year due to sharp decline in COVID and COVID-related revenue. The decline in COVID business has been to the extent of 80% to 85% compared to last year in general. Industry also experienced tough competitions in these couple of years, entry of many players coming from pharma, hospitals and even e-commerce as well. Most large players in the industry also haven't taken meaningful price increases in the last five to six years.  Bundling of tests may have led to higher realization per patient but has resulted in an effective decline in realization per test. It's very clear in recent trends that patients or consumers are looking for a higher level of convenience. Those days have gone, where people will come to a lab and stand in the queue and wait for 30-35 minutes for their turn to come and give blood samples. So, they are expecting collection to be done near them, which could be in the format

Business Overview LPL is an established consumer healthcare brand in diagnostic services and one of the largest companies offering exposure to this segment within healthcare in India. The foundation of this company was laid in 1949 by Dr. Major S. K. Lal, who is the father of Dr. Lal. LPL operates under a hub and spoke model. This includes LPL’s National Reference Laboratory which is located in New Delhi, supported by 175 clinical laboratories, 1,592 patient service centers and over 7,300 pickup points presently. Under this arrangement, samples are collected across multiple locations within a region and are forwarded to pre-designated clinical laboratories for centralized diagnostic testing. This provides the company greater efficiencies and of course better economies of scale while making available a scalable platform. LPL is networked across India, including large cities such as New Delhi, Mumbai, Bengaluru, Chennai, Hyderabad and Kolkata. A key factor which binds the LPL’s operation